Pfizer said its full-year 2009 revenues rose 4% to $50 billion, with US revenues up 7% over 2008 to $21.7 billion and international revenues up 1% to $28.3 billion. Fourth-quarter US revenues were up 42% compared to Q4 2008, while international revenues were up 28%.
GlaxoSmithKline announced its annual results, showing 3% sales growth for 2009, with sales from “white pills in western markets” down to 30% of full-year sales from 2008's 36%. Emerging markets sales were up 20%, while sales in Japan were up 22% and consumer healthcare product sales rose 7%. The company also announced the launch of a new specialist unit to research and develop drugs for rare diseases.